Exact Sciences (EXAS) EBITDA Margin (2010 - 2025)

Exact Sciences (EXAS) has 16 years of EBITDA Margin data on file, last reported at 9.4% in Q4 2025.

• EBITDA Margin for Q4 2025 came in at 9.4%, up 11343.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 6.35% (up 3166.0% YoY), and the FY2025 annual result was 6.35%, up 3166.0% from the prior year.
• EBITDA Margin retreated to 9.4% in Q4 2025 per EXAS's latest filing, from 3.0% in the prior quarter.
• Over five years, EBITDA Margin peaked at 1.09% in Q3 2023 and troughed at 122.84% in Q4 2024.
• A 5-year average of 26.05% and a median of 15.16% in 2024 frame the typical range for EBITDA Margin.
• The sharpest annual moves came in 2024 and 2025: EBITDA Margin tumbled 11235 bps in 2024, then soared 11343 bps in 2025.
• A 5-year view of EBITDA Margin shows it stood at 46.74% in 2021, then jumped by 54 bps to 21.5% in 2022, then jumped by 51 bps to 10.49% in 2023, then slumped by 1071 bps to 122.84% in 2024, then jumped by 92 bps to 9.4% in 2025.
• Business Quant data shows EXAS's EBITDA Margin at 9.4% in Q4 2025, 3.0% in Q3 2025, and 0.26% in Q2 2025.